系统性药理疗方法用于治疗系统性硬化症
Stefano Di Donato1,2,3, Zsuzsanna H McMahan4, Michael Hughes5,6
1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Expert opinion on pharmacotherapy
|February 21, 2025
概括
系统性硬化症 (SSc) 是一种复杂的疾病,需要更好的治疗方法. 本综述探讨了SSc表现现的当前治疗方法,并强调了需要个性化医疗来改善患者的治疗结果.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 纤维化研究 纤维化研究
背景情况:
- 系统性硬化症 (SSc) 是一种多系统性疾病,涉及免疫失调,血管问题和纤维化.
- SSc对患者的生活质量产生了重大影响,并提出了管理方面的挑战.
- 目前对SSc病变的理解有限,这阻碍了有效的治疗开发.
研究的目的:
- 审查目前对皮肤,肺部和血管并发症等SSc表现物的药理疗法.
- 根据最近的文献和指导方针,提供SSc管理策略的全面概述.
- 强调开发SSc.新型治疗策略的重要性.
主要方法:
- 对最近的研究和过去十年的临床试验进行文献综述.
- 对EULAR和ACR当前管理指南的分析.
- 对SSc.的可用治疗选择的综合分析.
主要成果:
- 现有的治疗方法解决了关键的SSc表现,包括皮肤,肺部和血管问题.
- 最近的进展为SSc患者提供了改进的管理选择.
- 尽管取得了进展,SSc由于其复杂性和有限的病原体理解,仍然具有挑战性.
结论:
- 完善现有的治疗方案和开发有针对性的疗法对于SSc管理至关重要.
- 个性化医疗方法和优化治疗算法对于改善患者的治疗结果至关重要.
- 需要进一步研究SSc的致病性,以制定更有效的策略.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
89
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
89
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
131
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
131
Myasthenia Gravis: Overview and Treatment
1.1K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
92
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
92
Drug Therapy
34
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
34


